Movement Alert｜Everest Medicines Rises 6.67% in Regular Trading, EVER001 Licensing Deal Closure and Biotech Sector Rally Drive Gains

Market Focus

Jul 15

On July 15, Everest Medicines rose 6.67% in regular trading, trading at HK$29.46/share, with turnover of HK$65.34 million. The stock was buoyed by a combination of company-specific catalysts and broad sector strength.

On the news front, Everest Medicines announced on July 8 the completion of its exclusive licensing and collaboration agreement with Travere Therapeutics for EVER001 (civorebrutinib), a BTK inhibitor targeting multiple immune-mediated kidney diseases. The deal involves a US$112.5 million upfront payment and up to US$1.03 billion in milestone payments, marking a key milestone in the company's global commercialization strategy. The transaction has now formally entered the implementation phase for joint development.

Meanwhile, the broader biotechnology sector exhibited strong momentum on the same day, with SKB Bio up 11.0%, Innovent Bio up 9.11%, Akeso up 8.82%, and 3SBio up 9.03%, providing additional sector-driven tailwinds to Everest Medicines' share price.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/news/1168685358"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1168685358\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1168685358?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-15 11:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1168685358","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Everest Medicines Rises 6.67% in Regular Trading, EVER001 Licensing Deal Closure and Biotech Sector Rally Drive Gains","media":"Market Focus","content":"<p><p>On July 15, Everest Medicines rose 6.67% in regular trading, trading at HK$29.46/share, with turnover of HK$65.34 million. The stock was buoyed by a combination of company-specific catalysts and broad sector strength.</p><p>On the news front, Everest Medicines announced on July 8 the completion of its exclusive licensing and collaboration agreement with Travere Therapeutics for EVER001 (civorebrutinib), a BTK inhibitor targeting multiple immune-mediated kidney diseases. The deal involves a US$112.5 million upfront payment and up to US$1.03 billion in milestone payments, marking a key milestone in the company's global commercialization strategy. The transaction has now formally entered the implementation phase for joint development.</p><p>Meanwhile, the broader biotechnology sector exhibited strong momentum on the same day, with SKB Bio up 11.0%, Innovent Bio up 9.11%, Akeso up 8.82%, and 3SBio up 9.03%, providing additional sector-driven tailwinds to Everest Medicines' share price.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Everest Medicines Rises 6.67% in Regular Trading, EVER001 Licensing Deal Closure and Biotech Sector Rally Drive Gains</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Everest Medicines Rises 6.67% in Regular Trading, EVER001 Licensing Deal Closure and Biotech Sector Rally Drive Gains\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-15 11:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 15, Everest Medicines rose 6.67% in regular trading, trading at HK$29.46/share, with turnover of HK$65.34 million. The stock was buoyed by a combination of company-specific catalysts and broad sector strength.</p><p>On the news front, Everest Medicines announced on July 8 the completion of its exclusive licensing and collaboration agreement with Travere Therapeutics for EVER001 (civorebrutinib), a BTK inhibitor targeting multiple immune-mediated kidney diseases. The deal involves a US$112.5 million upfront payment and up to US$1.03 billion in milestone payments, marking a key milestone in the company's global commercialization strategy. The transaction has now formally entered the implementation phase for joint development.</p><p>Meanwhile, the broader biotechnology sector exhibited strong momentum on the same day, with SKB Bio up 11.0%, Innovent Bio up 9.11%, Akeso up 8.82%, and 3SBio up 9.03%, providing additional sector-driven tailwinds to Everest Medicines' share price.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01952","symbol_name":"云顶新耀","start_time":0,"source_url":"","article_id":"1168685358","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1168685358","pubTimestamp":1784085041,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 15, Everest Medicines rose 6.67% in regular trading, trading at HK$29.46/share, with turnover of HK$65.34 million. The stock was buoyed by a combination of company-specific catalysts and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01952":"云顶新耀"},"translate_title":"走势警报|Everest Medicines 常规交易上涨 6.67%，EVER001 许可交易完成，生物技术板块反弹推动上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01952":1},"content_text":"On July 15, Everest Medicines rose 6.67% in regular trading, trading at HK$29.46/share, with turnover of HK$65.34 million. The stock was buoyed by a combination of company-specific catalysts and broad sector strength.On the news front, Everest Medicines announced on July 8 the completion of its exclusive licensing and collaboration agreement with Travere Therapeutics for EVER001 (civorebrutinib), a BTK inhibitor targeting multiple immune-mediated kidney diseases. The deal involves a US$112.5 million upfront payment and up to US$1.03 billion in milestone payments, marking a key milestone in the company's global commercialization strategy. The transaction has now formally entered the implementation phase for joint development.Meanwhile, the broader biotechnology sector exhibited strong momentum on the same day, with SKB Bio up 11.0%, Innovent Bio up 9.11%, Akeso up 8.82%, and 3SBio up 9.03%, providing additional sector-driven tailwinds to Everest Medicines' share price.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}